posted
MCET Avian Flu play at the lowest prices of the year and news out today sparking a price jump of 10 cents. The news is big, once they get human tests approved this stock can soar. If not, well I don't think it can go any lower than years low:
---------- Press Release Source: MultiCell Technologies, Inc.
MultiCell Nominates MCT-465 as Lead Drug Candidate for Evaluation in H5N1 Avian Flu Model Wednesday November 9, 8:30 am ET
LINCOLN, R.I.--(BUSINESS WIRE)--Nov. 9, 2005--MultiCell Technologies, Inc. (OTCBB:MCET - News) announced that its subsidiary, MultiCell ImmunoTherapeutics, has elevated MCT-465 to lead drug candidate status and will commence evaluation of MCT-465 in preclinical animal models infected with the H5N1 strain of influenza A virus, known as the "bird flu" or "avian flu" virus. These preclinical studies will seek to build on the success that MCTI's toll receptor molecule and lead drug candidate MCT-465 demonstrated in animal models infected with the H1N1 strain of influenza A virus. In these preclinical studies, originally published in the October 2002 Journal of Clinical Investigation, MCT-465 reduced pulmonary virus titers by 1,000-fold in mouse models, resulting in barely detectable levels of the virus. The results suggest MCT-465 may also be able to reduce influenza A H5N1 viral load. The H5N1 strain of influenza A virus is genetically similar to the H1N1 strain of influenza A virus.
The proposed studies will be designed to determine the effectiveness of MCT-465 to induce immunity in mice infected by the H5N1 influenza A virus. "Based upon our results with influenza A H1N1 virus in mouse models, we believe MCT-465 holds the promise of demonstrating efficacy in H5N1 influenza A animal models," said Dr. Stephen Chang, President of MultiCell. The Company plans additional preclinical studies to further elucidate the underlying immunology, as well as evaluate the manufacturing requirements and toxicology profile of MCT-465 prior to beginning human clinical trials. MultiCell acquired MCT-465 as a result of its acquisition last month of substantially all of the assets of Astral, Inc.
Posts: 137 | Registered: Dec 2004
| IP: Logged |
UBBFriend: Email this page to someone!
Printer-friendly view of this topic
